Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial.
Joyce F LiuStephanie GaillardAndrea E Wahner HendricksonOladapo O YekuElisabeth DiverCamille Gunderson JacksonRebecca ArendElena RatnerVivek SamnotraDivya GuptaJon ChungHailei ZhangNatalie ComptonAmanda BainesEmeline BacquéXiaohong LiuBrunella FelicettiGottfried E KonecnyPublished in: JCO precision oncology (2024)
, or PD-L1 status. AEs were consistent with previous monotherapy reports, except that hypertension was reported more frequently.